野村：维持翰森制药(03692)“中性”评级 目标价上调至17.23港元
野村发布报告称，将翰森制药(03692)目标价由15.03港元上调至17.23港元，维持“中性”评级，今年收入及盈利预测分别上调2.7%及6.9%，明年分别上调6%及0.7%，以反映抗体偶联药物(ADC)上半年收入表现，以及阿美替尼(Almonertinib)进展符合预期，抵销非专利药的销售压力。该行估计公司上半年收入及盈利同比升38.2%及86.1%。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.